In Vivo screening and discovery of novel candidate thalidomide analogs in the zebrafish embryo and chicken embryo model systems

Shaunna L. Beedie; Holly M. Rore; Shelby Barnett; Cindy H.  Chau; Weiming  Luo; Nigel H. Greig; William D. Figg; Neil Vargesson

doi:10.18632/oncotarget.8909

In Vivo screening and discovery of novel candidate thalidomide analogs in the zebrafish embryo and chicken embryo model systems

Shaunna L. Beedie, Holly M. Rore, Shelby Barnett, Cindy H. Chau, Weiming Luo, Nigel H. Greig, William D. Figg, Neil Vargesson

Research output: Contribution to journal › Article › peer-review

35 Citations (Scopus)

9 Downloads (Pure)

Abstract

Thalidomide, a drug known for its teratogenic side-effects, is used successfully to treat a variety of clinical conditions including leprosy and multiple myeloma. Intense efforts are underway to synthesize and identify safer, clinically relevant analogs. Here, we conduct a preliminary in vivo screen of a library of new thalidomide analogs to determine which agents demonstrate activity, and describe a cohort of compounds with anti-angiogenic properties, anti-inflammatory properties and some compounds which exhibited both. The combination of the in vivo zebrafish and chicken embryo model systems allows for the accelerated discovery of new, potential therapies for cancerous and inflammatory conditions.

Original language	English
Pages (from-to)	33237-33245
Number of pages	9
Journal	Oncotarget
Volume	7
Issue number	22
DOIs	https://doi.org/10.18632/oncotarget.8909
Publication status	Published - 22 Apr 2016

Bibliographical note

This study was supported by a Wellcome Trust-NIH
PhD Studentship to SB, WDF and NV. Grant number
098252/Z/12/Z. SB, CHC and WDF are supported by the Intramural Research Program, NCI, NIH. NHG and WL are supported by the Intramural Research Program, NIA, NIH.

Keywords

angiogenesis
inflammation
thalidomide
cancer
teratogenesis

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.18632/oncotarget.8909Licence: CC BY

In vivo screening and discovery of novel candidate thalidomide analogs in the zebrafish embryo and chicken embryo model systems
licensed under a Creative Commons Attribution 3.0 License http://creativecommons.org/licenses/by/3.0/
Final published version, 2.41 MBLicence: CC BY

Neil Vargesson
Person: Academic

Thalidomide research guides recognition and compensation for survivors born with Thalidomide damage
Neil Vargesson (Coordinator) & Lynda Erskine (Coordinator)
Impact

Cite this

@article{e3fe86ac67bf4f1b8a39aacf3508b4c0,

title = "In Vivo screening and discovery of novel candidate thalidomide analogs in the zebrafish embryo and chicken embryo model systems",

abstract = "Thalidomide, a drug known for its teratogenic side-effects, is used successfully to treat a variety of clinical conditions including leprosy and multiple myeloma. Intense efforts are underway to synthesize and identify safer, clinically relevant analogs. Here, we conduct a preliminary in vivo screen of a library of new thalidomide analogs to determine which agents demonstrate activity, and describe a cohort of compounds with anti-angiogenic properties, anti-inflammatory properties and some compounds which exhibited both. The combination of the in vivo zebrafish and chicken embryo model systems allows for the accelerated discovery of new, potential therapies for cancerous and inflammatory conditions.",

keywords = "angiogenesis, inflammation, thalidomide, cancer , teratogenesis",

author = "Beedie, {Shaunna L.} and Rore, {Holly M.} and Shelby Barnett and Chau, {Cindy H.} and Weiming Luo and Greig, {Nigel H.} and Figg, {William D.} and Neil Vargesson",

note = "This study was supported by a Wellcome Trust-NIH PhD Studentship to SB, WDF and NV. Grant number 098252/Z/12/Z. SB, CHC and WDF are supported by the Intramural Research Program, NCI, NIH. NHG and WL are supported by the Intramural Research Program, NIA, NIH.",

year = "2016",

month = apr,

day = "22",

doi = "10.18632/oncotarget.8909",

language = "English",

volume = "7",

pages = "33237--33245",

journal = "Oncotarget",

publisher = "IMPACT JOURNALS LLC",

number = "22",

}

TY - JOUR

T1 - In Vivo screening and discovery of novel candidate thalidomide analogs in the zebrafish embryo and chicken embryo model systems

AU - Beedie, Shaunna L.

AU - Rore, Holly M.

AU - Barnett, Shelby

AU - Chau, Cindy H.

AU - Luo, Weiming

AU - Greig, Nigel H.

AU - Figg, William D.

AU - Vargesson, Neil

N1 - This study was supported by a Wellcome Trust-NIH PhD Studentship to SB, WDF and NV. Grant number 098252/Z/12/Z. SB, CHC and WDF are supported by the Intramural Research Program, NCI, NIH. NHG and WL are supported by the Intramural Research Program, NIA, NIH.

PY - 2016/4/22

Y1 - 2016/4/22

N2 - Thalidomide, a drug known for its teratogenic side-effects, is used successfully to treat a variety of clinical conditions including leprosy and multiple myeloma. Intense efforts are underway to synthesize and identify safer, clinically relevant analogs. Here, we conduct a preliminary in vivo screen of a library of new thalidomide analogs to determine which agents demonstrate activity, and describe a cohort of compounds with anti-angiogenic properties, anti-inflammatory properties and some compounds which exhibited both. The combination of the in vivo zebrafish and chicken embryo model systems allows for the accelerated discovery of new, potential therapies for cancerous and inflammatory conditions.

AB - Thalidomide, a drug known for its teratogenic side-effects, is used successfully to treat a variety of clinical conditions including leprosy and multiple myeloma. Intense efforts are underway to synthesize and identify safer, clinically relevant analogs. Here, we conduct a preliminary in vivo screen of a library of new thalidomide analogs to determine which agents demonstrate activity, and describe a cohort of compounds with anti-angiogenic properties, anti-inflammatory properties and some compounds which exhibited both. The combination of the in vivo zebrafish and chicken embryo model systems allows for the accelerated discovery of new, potential therapies for cancerous and inflammatory conditions.

KW - angiogenesis

KW - inflammation

KW - thalidomide

KW - cancer

KW - teratogenesis

U2 - 10.18632/oncotarget.8909

DO - 10.18632/oncotarget.8909

M3 - Article

C2 - 27120781

VL - 7

SP - 33237

EP - 33245

JO - Oncotarget

JF - Oncotarget

IS - 22

ER -

In Vivo screening and discovery of novel candidate thalidomide analogs in the zebrafish embryo and chicken embryo model systems

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Fingerprint

Profiles

Neil Vargesson

Impacts

Thalidomide research guides recognition and compensation for survivors born with Thalidomide damage

Cite this